Health and Fitness

Study assesses the efficacy and security of lithium remedy in sufferers contaminated with extreme SARS-CoV-2

In a current research printed within the Frontiers in Pharmacology journal, researchers assessed the efficacy and security of utilizing lithium for coronavirus illness 2019 (COVID-19) remedy.

Study: Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. Image Credit: tunasalmon/Shutterstock
Study: Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. Image Credit: tunasalmon/Shutterstock

Administering extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has been the only real technique for combating the pandemic to this point. However, the fixed emergence of novel variants, refusal of a piece of most of the people to obtain vaccines, and the rising variety of hospitalizations in SARS-CoV-2-infected people have necessitated the event of a potent antiviral agent.

About the research

In the current research, researchers carried out a medical trial to estimate the efficacy and security of utilizing lithium as a remedy technique in extreme COVID-19 sufferers.

The group executed a potential, longitudinal, and comparative research between two teams: (1) a management group comprising COVID-19 sufferers handled with a regular technique of remedy utilizing dexamethasone and (2) an experimental group comprising COVID-19 sufferers with dexamethasone in addition to lithium carbonate. The experimental cohort was administered 200 mg each 12 hours of lithium carbonate administration, making certain that the plasma ranges have been between 0.6 mEq/ L and 1.2 mEq/ L.

COVID-19-positive sufferers admitted to the Hospital Álvaro Cunqueiro, Spain, have been included within the research. The sufferers eligible for the research have been aged 18 years and above and didn’t require admission to the intensive care unit (ICU) on the time of research enrolment. All the sufferers have been confirmed to be COVID-19 constructive by reverse transcription-polymerase chain response (RT-PCR). The group carried out 1:1 randomization taking into consideration the gender and age of the sufferers. The group additionally obtained plasma samples to find out cytokines through enzyme-linked immunosorbent assay (ELISA) quantitatively. Levels of c-reactive protein (CRP) and absolute lymphocyte depend have been additionally recorded.

The group additionally carried out a multiplex one-step real-time RT-PCR to establish an exogenous ribonucleic acid (RNA)-based inside management (IC) and 4 viral targets such because the structural protein envelope (E) gene, the nucleocapsid (N) gene, the RNA-dependent RNA polymerase (RdRP) gene, and the spike (S) gene. Furthermore, the serological analysis of the samples was carried out utilizing chemiluminescent immunoassay (CLIA) assays.

The main final result of the research included the measurement of the length of hospitalization and the variety of sufferers that required ICU admission. The secondary outcomes included the analysis of medical and analytical parameters.


The research outcomes confirmed that among the many 30 sufferers eligible for the analysis, 30% reported hypertension, 20% had dyslipidemia, and 16% had weight problems. No opposed results of the lithium carbonate remedy have been noticed in any of the sufferers. The group discovered that lithium remedy decreased the general variety of days of hospitalization because the management group spent 12.43 days and the lithium group spent 6.47 days within the hospital. Notably, not one of the sufferers handled with lithium carbonate required ICU admission whereas no deaths have been reported. On the opposite hand, within the management group, two sufferers wanted ICU admission, and one affected person succumbed to demise. 

Evaluation of the management and the experimental teams throughout hospitalization confirmed that lithium remedy considerably improved blood lymphocyte ranges. However, the lymphocyte ranges returned to regular ranges at discharge. Furthermore, lymphoma was noticed within the management group sufferers for 9.79 ± 11.14 days and within the lithium-treated group for 3.87 ± 2.53 days. The group additionally noticed a major response towards irritation after lithium remedy. This was famous within the discount in interleukin-6 (IL-6), IL-10, and tumor necrosis issue α (TNFα) ranges within the lithium-treated group in comparison with the management cohort.    

Moreover, the estimation of the neutrophil-lymphocyte ratio (NLR) and the CRP ranges confirmed that remedy with lithium decreased NLR and CRP ranges to low extents. This was evidenced because the NLR ranges have been 116 ± 53.94 and 40.06 ± 6.544 whereas the CRP ranges have been 1323 ± 491.4 and 549.7 ± 100.9 within the management and lithium-treated cohorts, respectively. Lithium remedy additionally lowered the degrees of IL-12, IL1b, programmed death-ligand 1 (PD-L1), inducible protein-10 (IP-10), interferon-gamma (IFN-γ), and tissue inhibitor of metalloproteinase-3 (TIMP3). The group additionally discovered that lithium remedy decreased ranges of ferritin and D-dimer.  


The research findings confirmed that remedy with lithium carbonate was protected and efficacious in treating and curbing illness severity in COVID-19-infected sufferers. Lithium sufficiently decreased the degrees of inflammatory cytokines, thus lowering the probability of severity of an infection and threat of demise. The researchers imagine extreme COVID-19 remedy with lithium requires additional investigation and evaluation.  


Source hyperlink

Leave a Reply

Your email address will not be published.